Overview
From a portfolio lens, Injective ($490.41M) and GLM ($91.80M) offer different beta to bitcoin cycles. The overview below keeps the facts first and the narrative second.
Quick winners
Full comparison
| Metric | INJ | GLM |
|---|---|---|
| Price | $5.08 | $0.092000 |
| Market Cap | $490.41M | $91.80M |
| FDV | — | — |
| Volume 24h | $2.27M | $26,943.55 |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 270.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | GLM |
|---|---|---|
| 1H | — | — |
| 24H | +4.65% | +0.00% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | GLM |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.47 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 63.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Technically, Injective shows RSI 49.29 with trend bias neutral, while GLM sits at RSI 49.02 (bearish). Divergences between momentum and price should be confirmed on higher timeframes.
Fundamentals
| Metric | INJ | GLM |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
GLM
Pros and cons
Pros of Injective
- Composite PEPS readings for Injective can surface clearer module agreement during trend phases.
- Injective has an established coin page footprint on PEPS for continuous monitoring.
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
- Higher ranking for Injective can translate into tighter spreads on major venues.
Cons of Injective
- Regulatory or macro headlines can hit Injective harder simply because it is more visible.
- When dominance narratives fade, Injective can lag hotter rotation names.
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
Pros of GLM
- Diversifying versus Injective with GLM can change portfolio factor exposure.
- Narrative optionality around GLM can reprice quickly when catalysts appear.
- GLM can offer higher relative beta when market attention rotates toward its niche.
Cons of GLM
- Weaker market-cap standing may leave GLM more exposed to liquidity droughts.
- Trend failures on GLM often travel faster than on more established assets.
- Relative underperformance versus Injective can persist through entire market regimes.
Which looks stronger right now?
On the latest snapshot, market-cap leadership belongs to Injective, while short-term performance leans toward Injective. That mix suggests relative strength can flip quickly, so size risk accordingly.
AI summary
This AI-assisted summary starts from live PEPS fields. Injective holds market-cap $490.41M and rank #99; GLM shows $91.80M and #270. Where liquidity and flow matter, watch Injective. Where durability matters, watch Injective. AI composite scores (47.50/58.40) compress those tensions into a single lens. In probabilistic terms, the side winning more columns may have a nearer-term edge, but tails remain fat. Revisit after the next hourly refresh.
FAQ
Which is better, Injective or GLM?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or GLM?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and GLM.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.